Total Holdings
64
Portfolio diversification across 64 positions

Complete portfolio holdings with allocation weights, sector breakdown, and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
View ticker symbols, company names, asset types, and allocation percentages for each position
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 | ![]() | Revolution Medicines, Inc | Stock | 5.65% |
| 2 | ![]() | Moderna, Inc. | Stock | 5.51% |
| 3 | E ETR:BAYN | Bayer Aktiengesellschaft | Stock | 5.09% |
| 4 | T TYO:4502 | Takeda Pharmaceutical Company Limited | Stock | 4.69% |
| 5 | L LON:GSK | GSK plc | Stock | 4.57% |
| 6 | ![]() | Merck & Co., Inc. | Stock | 4.49% |
| 7 | S SWX:ROG | Roche Holding AG | Stock | 4.46% |
| 8 | T TSE:4502 | Takeda Pharmaceutical Co. Ltd. | Stock | 4.30% |
| 9 | E EPA:IPN | Ipsen S.A. | Stock | 4.21% |
| 10 | ![]() | Regeneron Pharmaceuticals, Inc | Stock | 4.21% |
| 11 | ![]() | BioNTech SE | Stock | 4.10% |
| 12 | C CO:GMAB | Genmab A/S | Stock | 4.07% |
| 13 | ![]() | Incyte Corporation | Stock | 3.96% |
| 14 | ![]() | Vertex Pharmaceuticals Incorporated | Stock | 3.87% |
| 15 | ![]() | Exelixis, Inc | Stock | 3.77% |
| 16 | C CPH:GMAB | Genmab A/S | Stock | 3.70% |
| 17 | ![]() | Caris Life Sciences, Inc. Common Stock | Stock | 3.66% |
| 18 | E EPA:SAN | Sanofi | Stock | 3.61% |
| 19 | ![]() | Ideaya Biosciences Inc | Stock | 3.49% |
| 20 | ![]() | Arcellx Inc | Stock | 3.19% |
| 21 | ![]() | Twist Bioscience Corporation | Stock | 3.01% |
| 22 | ![]() | Nuvation Bio Inc | Stock | 2.14% |
| 23 | T TYO:4528 | Ono Pharmaceutical Co., Ltd. | Stock | 2.06% |
| 24 | ![]() | ImmunityBio, Inc. | Stock | 2.05% |
| 25 | T TSE:4528 | Ono Pharmaceutical Ltd | Stock | 1.92% |
| 26 | ![]() | CRISPR Therapeutics AG | Stock | 1.86% |
| 27 | ![]() | Arcus Biosciences, Inc | Stock | 1.75% |
| 28 | ![]() | Novavax, Inc. | Stock | 1.28% |
| 29 | ![]() | Iovance Biotherapeutics, Inc | Stock | 0.91% |
| 30 | ![]() | Kura Oncology Inc | Stock | 0.88% |
| 31 | ![]() | Janux Therapeutics Inc | Stock | 0.85% |
| 32 | ![]() | Rigel Pharmaceuticals Inc | Stock | 0.81% |
| 33 | ![]() | CytomX Therapeutics, Inc | Stock | 0.62% |
| 34 | ![]() | Vir Biotechnology, Inc | Stock | 0.61% |
| 35 | ![]() | Pacific Biosciences of California, Inc | Stock | 0.58% |
| 36 | ![]() | Verastem, Inc | Stock | 0.56% |
| 37 | ![]() | Ocugen, Inc | Stock | 0.52% |
| 38 | ![]() | Personalis, Inc | Stock | 0.48% |
| 39 | H HKG:2696 | Shanghai Henlius Biotech Inc | Stock | 0.45% |
| 40 | ![]() | Ginkgo Bioworks Holdings Inc. | Stock | 0.44% |
| 41 | ![]() | Corvus Pharmaceuticals Inc | Stock | 0.43% |
| 42 | ![]() | Intellia Therapeutics, Inc | Stock | 0.43% |
| 43 | ![]() | Xencor, Inc | Stock | 0.35% |
| 44 | ![]() | Design Therapeutics, Inc. Common Stock | Stock | 0.33% |
| 45 | ![]() | Prime Medicine Inc. Common Stock | Stock | 0.14% |